Teva (TEVA +0.65%) yesterday sued Dutch firm Synthon in New York for infringing seven patents as...


Teva (TEVA +0.65%) yesterday sued Dutch firm Synthon in New York for infringing seven patents as it readies plans to sell a generic version of Teva's blockbuster multiple sclerosis drug Copaxone before the patents expire. Synthon argues that Teva's claims are invalid or unenforceable.
From other sites
Comments (1)
  • itasara
    , contributor
    Comments (21) | Send Message
     
    As a consumer and user of this drug, as much as I would like to stand up for a company's patent rights, I can only say I am looking forward to a generic form of this drug as long as it is as effective and as long as it costs a lot less than the current cost of copaxone. If Teva plans to come out with its own generic form, I would be all for that too, but when is that going to happen? The 7 yr patent should be coming to end end soon, shouldn't it? And what are these lawsuits costing Teva? By the time the FDA would approve a generic form won't the Teva Patents have expired? Although most the cost of the drug is paid for by insurance companies for those who have coverage, the overall cost of the drug has gone up over $230 year to approximately $22,000/ year. I realize and hope some of the profit may go to research and some to help those without insurance, but it is still a very costly drug which might help more if it were not so expensive.
    6 Apr 2012, 12:36 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs